1. Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents
- Author
-
Venceslau Hespanhol, Henrique Queiroga, Natália Cruz-Martins, Cláudia Freitas, David Araújo, Conceição Souto-Moura, Maria Jacob, Adriana Magalhães, Nuno Tavares, Vanessa Santos, Hélder Novais-Bastos, and Gabriela Fernandes
- Subjects
0301 basic medicine ,Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Neutrophils ,ECOG Performance Status ,Comorbidity ,Systemic therapy ,Severity of Illness Index ,Prognostic score ,Cigarette Smoking ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,Carcinoma ,medicine ,Biomarkers, Tumor ,Humans ,Pharmacology (medical) ,Lymphocytes ,Neoplasm Metastasis ,Adverse effect ,Anti pd1 ,Immune Checkpoint Inhibitors ,Aged ,Pharmacology ,Aged, 80 and over ,Lung ,business.industry ,Middle Aged ,medicine.disease ,Prognosis ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Female ,Non small cell ,Inflammation Mediators ,business - Abstract
Immune checkpoint inhibitors were approved for advanced nonsmall cell lung cancer (NSCLC) treatment. Despite improved survival, not all patients benefit from these agents. Here, the prognostic impact of pretreatment modified Glasgow Prognostic Score (mGPS) and neutrophil-to-lymphocyte ratio (NLR) was assessed. From 77 patients included, 83.2% received at least one prior systemic therapy. Immune-related adverse events (irAE) occurred in 20 patients. A lower mGPS was associated with higher median overall survival (OS), and a lower Eastern Cooperative Oncology Group (ECOG), irAE and fewer metastatic sites with better survival. A trend towards greater OS and progression-free survival (PFS) was stated among patients with NLR5. mGPS 0 was associated with better survival; ≥3 metastatic sites with worse PFS and OS; ECOG2 with worse OS and irAE with better survival. Pretreatment mGPS seems to be useful for predicting survival among advanced NSCLC patients treated with anti-programmed cell death 1 drugs, with ECOG performance status, irAE occurrence, and number of metastatic sites acting as survival predictors.
- Published
- 2021